Skip to main content
. 2022 Oct 5;13:1012294. doi: 10.3389/fphar.2022.1012294

TABLE 6.

Summary of AEs for Cefaclor granule and Cefaclor suspension in postprandial trial.

AE category Cefaclor granule Cefaclor suspension
N n N n
Total adverse events 2 2 1 1
AEs related to the study drugs 2 2 1 1
Anemia 1 1 0 0
Infection urinary tract 0 0 0 0
Urinary occult blood positive 1 1 1 1
AEs of grade 1 2 2 1 1
AEs of grade 2 0 0 0 0
AEs of grade 3 and above 0 0 0 0
AEs leading to discontinuation of study drug 0 0 0 0

N, number of the subjects with adverse events; n, the number of adverse events; AEs, adverse events.